Category: Vaccine

(The Hill) A Centers for Disease Control and Prevention (CDC) study has found that mRNA vaccines for the COVID-19 virus are not linked to cardiac death in younger adults.

The study was conducted using Oregon death certificate data for people aged 16 to 30 who died from a heart condition between June 1, 2021 and Dec. 31, 2022. The study was done after cases of myocarditis, an inflammation of the heart muscle, were reported to the Vaccine Adverse Event Reporting System.

Of the 40 people who died who had a COVID vaccine dose, three died within 100 days of receiving their vaccination. Two were because the person had an underlying illness and one had an undetermined cause of death, the CDC said.

The data do not support an association of COVID-19 vaccination with sudden cardiac death among previously healthy young persons, the CDC said.

While the risk of dying due to myocarditis was higher for younger people during 2021, the CDC found that it remained an infrequent cause of death among the age group.

During the same time period, 30 Oregon residents in the same age group died from COVID and only three of the people who died had received any sort of COVID vaccine.

The CDC said the report cant exclude vaccine-related cardiac deaths after the 100-day mark, but published data indicate that potential adverse effects associated with vaccinations tend to occur within 42 days of vaccine receipt.

The study also noted that the small population size made it less likely to see a rare event such as sudden cardiac death among the age group.

The CDC maintains that a COVID vaccination is recommended for all people 6 months and older to prevent infection, complications and death.

Excerpt from:

COVID vaccines not linked to cardiac death in young people: CDC study - CBS 4 Indianapolis

The drive-through event is being held in the parking lot of Friends of Indianapolis Dogs Outside at 1505 N. Sherman Drive.

INDIANAPOLIS One local animal non-profit organization is offering Hoosiers an opportunity to get their dogs vaccinated for free.

Indy's Parvo Prevention Project is hosting a free parvo vaccination clinic from 11 a.m. to 3 p.m. for local dogs April 13, and another one May 11.

Canine parvovirus is a highly contagious virus that spreads from dogs and can potentially be lethal.

Too many dogs arent getting the affordable and effective vaccinations for the highly lethal, expensive-to-treat Parvovirus, and the results are heartbreaking, said Robin Herman, the founder of LDR Rescue and organizer of the event.

Herman said the circumstance is especially regrettable, given the low cost of the vaccine.

When new puppy owners meet with most vets for the first time, they are confronted with packaged options that can run up to several hundred dollars, she said. If they do nothing else, they should ask for the Parvo vaccine, which can cost as little as $16.

Herman, who has rescued more than 1,400 dogs in her career, said the goal of Indys Parvo Prevention Project is to inoculate at least 500 dogs at the clinic.

The drive-through event is being held in the parking lot of Friends of Indianapolis Dogs Outsideat 1505 N. Sherman Dr.

For more information on the organizations and event, click here.

View post:

Indy non-profit hosting free parvo-vaccination clinic for dogs | wthr.com - WTHR

More Videos

Next up in 5

Example video title will go here for this video

Next up in 5

Example video title will go here for this video

There is no evidence that the vaccine is linked to heart disease, the agency says.

Author: 11alive.com

Published: 5:47 PM EDT April 12, 2024

Updated: 5:47 PM EDT April 12, 2024

Continued here:

CDC: COVID vaccine not linked to heart issues - 11Alive.com WXIA

Dear Savvy Senior,

My husband and I recently turned 65 and would like to find out which vaccines are recommended and covered by Medicare?

New beneficiaries

Dear New, All recommended vaccines for adults age 65 and older should be covered by either Medicare Part B or Part D, but there are some coverage challenges you should be aware of. Heres a rundown of which vaccines are recommended by the Centers for Disease Control and Prevention (CDC) and how Medicare covers them.

COVID-19: Even though COVID-19 is no longer a public health emergency, it can still cause severe illness, particularly in older adults. Because the COVID virus continues to mutate, new vaccines are being developed to keep pace, so the CDC recommends that all seniors stay up to date with the latest COVID vaccines, including booster shots.

All COVID-19 shots are covered 100 percent by Medicare Part B.

Flu: Considered an annual vaccination, most people of all ages receive flu shots in the fall when flu season begins. The CDC recommends seniors, 65 and older get a high-dose flu shot for extra protection beyond what a standard flu shot offers. The Fluzone High Dose Quadrivalent, FLUAD Quadrivalent and FluBlok Quadrivalent are your three options.

Annual flu shots are covered under Medicare Part B.

Pneumonia: These vaccines help protect against pneumococcal disease, which can cause pneumonia, meningitis and other infections. The CDC recommends everyone 65 and older get a pneumococcal vaccine. There are several different vaccine options available, so talk to your doctor or pharmacists to find out which is best for you or visit the CDCs Pneumococcal Vaccination webpage at CDC.gov/vaccines/vpd/pneumo/public/index.html.

Medicare Part B covers both single-dose and two-dose pneumococcal shots once in your lifetime.

Shingles: Caused by the same virus that causes chicken pox, shingles is a painful, blistering skin rash that affects more than 1 million Americans every year. All people over age 50 are recommended to get the two-dose Shingrix vaccine, which is given two to six months apart, even if you previously received Zostavax. In 2020, Shingrix replaced Zostavax, which is no longer available in the U.S.

All Medicare Part D prescription drug plans cover shingles vaccinations, but coverage amounts, and reimbursement rules vary depending on where the shot is given. Check your plan.

Tdap: Tetanus, diphtheria, and pertussis (whooping cough) are diseases caused by bacteria that can lead to serious illness and death. Therefore, a one-time dose of the Tdap vaccine is recommended for all adults. If youve already had a Tdap shot, you should get a tetanus-diphtheria (Td) booster shot every 10 years.

All Medicare Part D plans cover these vaccinations.

RSV: Respiratory syncytial virus (RSV) can lead to pneumonia or bronchiolitis and can worsen other chronic conditions common among older adults, such as asthma and chronic obstructive pulmonary disease (COPD). The CDC recommends all adults, age 60 and older, talk to their doctor about getting one of the RSV vaccines (either Arexvy or Abrysvo), usually in the fall and winter months when the virus is most prevalent.

Most Medicare Part D plans cover the RSV vaccine, but not all. If your plan doesnt cover it, you can ask for a coverage exception. You can also pay for the shot out of pocket and then follow-up with your plan to get reimbursed. If you pay for the shot upfront, your plan must pay you back.

There are other vaccines you may need depending on your health, lifestyle or travel plans. To help you get a handle on which ones are appropriate for you, take the CDCs What Vaccines Do You Need? quiz at www2.cdc.gov/nip/adultimmsched. Also, talk to your doctor during your next visit about what vaccinations you should get.

Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.org. Jim Miller is a contributor to the NBC Today show and author of The Savvy Senior book.

Read more:

On Medicare? These vaccinations are covered. - East Idaho News

Electronic health record data from 40 U.S. health care systems during January 2021January 2022, showed that the risk for cardiac complications was significantly higher after COVID-19 infection than after mRNA COVID-19 vaccination among persons aged 5 years (8). Data from CDCs National Center for Health Statistics show a background mortality rate from diseases of the heart among Oregonians aged 1534 years of 2.9 and 4.1 deaths per 100,000, during 2019 and 2021, respectively. Although the rate was higher during the pandemic year of 2021, myocarditis remained an infrequent cause of death among persons in this age group. Detection of a small difference in mortality rate from myocarditis would require a larger sample size.

In this study of 1,292 deaths among Oregon residents aged 1630 years during June 2021December 2022, none could definitively be attributed to cardiac causes within 100 days of receipt of an mRNA COVID-19 vaccine dose; one male died from undetermined causes 45 days after receipt of a COVID-19 vaccine. During May 1, 2021December 31, 2022, a total of 979,289 doses of COVID-19 vaccines were administered to Oregonians aged 1630 years (unpublished data, ALERT IIS, 2024.)

During the same period, COVID-19 was cited as the cause of death for 30 Oregon residents in this age group. Among these 30 decedents, ALERT IIS had records for 22 (73%), only three of whom had received any COVID-19 vaccination. Studies have shown significant reductions in COVID-19related mortality among vaccinated persons; during the first 2 years of COVID-19 vaccine availability in the United States, vaccination prevented an estimated 18.5 million hospitalizations and 3.2 million deaths (9).

The findings in this report are subject to at least two limitations. First, this report cannot exclude the possibility of vaccine-associated cardiac deaths >100 days after COVID-19 vaccine administration. However, published data indicate that potential adverse events associated with vaccinations tend to occur within 42 days of vaccine receipt (10). Second, small population size made it less likely that Oregon would see a rare event such as sudden cardiac death among adolescents and young adults.

These data do not support an association between receipt of mRNA COVID-19 vaccine and sudden cardiac death among previously healthy young persons. COVID-19 vaccination is recommended for all persons aged 6 months to prevent COVID-19 and complications, including death.

See the original post:

Assessment of Risk for Sudden Cardiac Death Among... - CDC

Liver cancer is the sixth most common cancer in the world. Researchers estimate 905,700 people were diagnosed with liver cancer in 2020 and that number is expected to hit 1.4 million by 2040.

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, accounting for more than 80% of all cases.

One of the newest treatment options for HCC is immunotherapy a treatment using a persons own immune system to fight the cancer. However, past studies show only 1520% of HCC diagnoses respond to immunotherapy and about 30% may be resistant.

Now, the results of a preliminary clinical trial show that people with HCC treated with immunotherapy and a personalized anti-tumor vaccine were twice as likely to experience tumor shrinkage compared to those receiving immunotherapy only.

The results of the trial were published April 7 in Nature Medicine.

This preliminary clinical trial was for GNOS-PV02 a personalized DNA vaccine created by Geneos Therapeutics.

Essentially GNOS-PV02 aims to (educate) the immune system to recognize antigens that are present in the cancer so that the immune system can better recognize and attack cancer cells, explained lead study author Mark Yarchoan, MD, associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.

The vaccine is personalized for each individual patients cancer. Just the way that every person has a unique fingerprint, every cancer has its own set of unique antigens that are derived from unique DNA mutations within the cancer, Yarchoan told Medical News Today.

To make a personalized vaccine, first a biopsy is obtained of the cancer, and the cancer DNA is sequenced to identify the potential unique antigens within the cancer. Then a personalized vaccine is manufactured that encodes the unique antigens identified in the analysis of the tumor biopsy.

Mark Yarchoan, MD, lead study author

GNOS-PV02 was used in conjunction with the immunotherapy drug pembrolizumab, known under the brand name Keytruda.

The Food and Drug Administration (FDA) granted approval for pembrolizumab for the treatment of HCC in November 2018.

Despite recent advances in the treatment of HCC, only a minority of patients respond to contemporary systemic treatments and the prognosis for patients with advanced disease is inferior to most other tumor types, Yarchoan said.

Yarchoan noted that until recently, most cancer vaccines failed in the clinic, citing a number of potential reasons as to why.

One reason is that past cancer vaccines usually targeted antigens that werent specific enough to the cancer, he said. Most cancer antigens are unique to an individual cancer, and the technology to personalize cancer vaccines has only been possible very recently.

But the other reason why cancer vaccines generally failed in the clinic is that they were used against advanced cancers, without any other immunotherapy, Yarchoan continued.

Weve learned that vaccines can cause immune cells to become exhausted before they can eliminate cancer cells. For this reason, contemporary cancer vaccines are often combined with other immune-activating therapies like pembrolizumab. This prevents the vaccine-induced T cells from becoming exhausted, he explained.

Researchers recruited 36 participants for this clinical trial. All participants received the combination of GNOS-PV02 vaccine and pembrolizumab.

At the end of the study, researchers found that almost one-third of participants experienced tumor shrinkage, which is about twice as many people seen in studies of immunotherapy alone for HCC.

Additionally, about 8% of the study participants had no evidence of a tumor after receiving the combination treatment.

The response rate on this study is high enough that I think its unlikely that the pembrolizumab alone did this it supports the idea that the vaccine contributed to the efficacy observed, Yarchoan said.

I think its also notable that the response rate was higher than pembrolizumab alone without a major increase in toxicity.

I think the results are highly encouraging, but larger randomized studies are needed to confirm the efficacy of personalized cancer vaccines and to define the optimal treatment sequence for their use. Larger clinical studies are being planned by (Geneos Therapeutics) and Im hopeful that such studies will confirm that this vaccine is an active agent.

Mark Yarchoan, MD, lead study author

After reviewing the results of this study, Anton Bilchik, MD, PhD, surgical oncologist, chief of medicine and Director of the Gastrointestinal and Hepatobiliary Program at Providence Saint Johns Cancer Institute in Santa Monica, CA, told MNT he was absolutely astonished at the results in this early vaccine trial.

HCC is one of the most common cancers in the world and its typically been very resistant to treatment, Bilchik explained. Recently, immunotherapy has been introduced as a possible treatment for patients with advanced HCC, but the response rates for immunotherapy have not been great.

What this study does is take patients own tumor and create a personalized vaccine, which doubles the response of the immunotherapy that is currently used for HCC, he continued. Not only are the results astonishing, but these are patients that have failed first-line treatment and are not amenable to resection or transplantation.

MNT also spoke with Martin Gutierrez, MD, director of Phase I research at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, about this study.

(This is) very encouraging news, Gutierrez commented. (The next research step should be a) larger Phase II trial in first-line therapy.

When asked if we will see more personalized cancer vaccines in the future, Bilchik said absolutely.

This is the future. And what makes this approach unique is that not only are they using the patients own tumor biopsy cells to identify these mutations, but they take it a step further by using these computational algorithms to predict which genes can be recognized by the patients own immune system. So this is getting into the field of really advanced technology and then ultimately artificial intelligence.

Anton Bilchik, MD, PhD, surgical oncologist

Visit link:

Liver cancer vaccine with immunotherapy shows promise in new trial - Medical News Today

Doses of cholera vaccine are being given to patients as fast as they are produced and the global stockpile has run completely dry, as deadly outbreaks of the disease continue to spread.

This does not shock anyone in the field of emergency epidemic response because the vaccine stockpile has been precariously low for years.

The surprise the good news, which is in itself surprising since cholera and good news are rarely used together is that three new vaccine makers are setting up production lines and joining the effort to replenish the stockpile.

And a fourth company, the only one that currently makes the vaccine, which is given orally, has been working at a pace that experts describe as heroic to expand its production.

Yet even with all this, the total global supply of the vaccine that will become available this year will be, at best, a quarter of what is needed.

At the end of February, countries had already reported 79,300 cases and 1,100 deaths from cholera this year. Since there is no uniform system for counting cases, this is most likely a gross underestimate.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit andlog intoyour Times account, orsubscribefor all of The Times.

Thank you for your patience while we verify access.

Already a subscriber?Log in.

Want all of The Times?Subscribe.

Visit link:

Global Stockpile of Cholera Vaccine Is Gone as Outbreaks Spread - The New York Times

In a historic move, Nigeria has become the first country in the world to roll out a new vaccine (called Men5CV) recommended by the World Health Organization (WHO), which protects people against five strains of the meningococcus bacteria. The vaccine and emergency vaccination activities are funded by Gavi, the Vaccine Alliance, which funds the global meningitis vaccine stockpile, and supports lower-income countries with routine vaccination against meningitis.

Nigeria is one of the 26 meningitis hyper-endemic countries of Africa, situated in the area known as the African Meningitis Belt. Last year, there was a 50% jump in annual meningitis cases reported across Africa.

In Nigeria, an outbreak of Neisseria meningitidis (meningococcus) serogroup C outbreak led to 1742 suspected meningitis cases, including 101 confirmed cases and 153 deaths in seven of 36 Nigerian states (Adamawa, Bauchi, Gombe, Jigawa, Katsina, Yobe, Zamfara) between 1 October 2023 and 11 March 2024. To quell the deadly outbreak, a vaccination campaign has been undertaken on 25--28 March 2024 to initially reach more than one million people aged 1-29 years.

Meningitis is a serious infection that leads to the inflammation of the membranes (meninges) that surround and protect the brain and spinal cord. There are multiple causes of meningitis, including viral, bacterial, fungal and parasitic pathogens. Symptoms often include headache, fever and stiff neck. Bacterial meningitis is the most serious, can also result in septicaemia (blood poisoning), and can seriously disable or kill within 24 hours those that contract it.

Meningitis is an old and deadly foe, but this new vaccine holds the potential to change the trajectory of the disease, preventing future outbreaks and saving many lives, said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. Nigerias rollout brings us one step closer to our goal to eliminate meningitis by 2030.

The revolutionary new vaccine offers a powerful shield against the five major strains of the meningococcal bacteria (A, C, W, Y and X) in a single shot. All five strains cause meningitis and blood poisoning. This provides broader protection than the current vaccine used in much of Africa, which is only effective against the A strain.

The new vaccine has the potential to significantly reduce meningitis cases and advance progress in defeating meningitis. This is especially important for countries like Nigeria where multiple serogroups are prevalent. The new vaccine uses the same technology as the meningitis A conjugate vaccine (MenAfriVac), which wiped out meningococcal A epidemics in Nigeria.

Northern Nigeria, particularly the states of Jigawa, Bauchi and Yobe were badly hit by the deadly outbreak of meningitis, and this vaccine provides health workers with a new tool to both stop this outbreak but also put the country on a path to elimination, said Prof. Muhammad Ali Pate of the Nigerian Ministry of Health and Social Welfare. Weve done a lot of work preparing health workers and the health system for the rollout of this new vaccine. We got an invaluable support from our populations despite this fasting period and from our community leaders especially the Emir of Gumel in Jigawa state who personally launched the vaccination campaign in the state. Well be monitoring progress closely and hopefully expanding the immunization in the coming months and years to accelerate progress.

This new multivalent conjugate vaccine was 13 years in the making and was based on a partnership between PATH and the Serum Institute of India. Financing from the UK governments Foreign, Commonwealth and Development Office was critical to its development.

In July 2023, WHO prequalified the new Men5CV vaccine (which has brand name MenFive) and in October 2023 issued an official recommendation to countries to introduce the new vaccine. Gavi allocated resources for the Men5CV rollout in December 2023, which is currently available for outbreak response through the emergency stockpile managed by the International Coordinating Group (ICG) on Vaccine Provision, while roll-out through mass preventive campaigns is expected to start in 2025 across countries of the Meningitis Belt.

The rollout of one million vaccines in northern Nigeria will help save lives, prevent long-term illness and boost our goal of defeating meningitis globally by 2030, said Andrew Mitchell, UK Minister for Development and Africa. This is exactly the kind of scientific innovation, supported by the UK, which I hope is replicated in years to come to help us drive further breakthroughs, including wiping out other diseases.

WHO has been supporting the Nigeria Centre for Disease Control and Prevention (NCDC) in responding to the meningitis outbreak in the country. This includes disease surveillance, active case finding, sample testing, and case management. WHO and partners have also played a vital role in supporting Nigeria to prepare for the rollout of the new vaccine and training health workers.

Year after year, meningococcal meningitis has tormented countries across Africa, said Dr Nanthalile Mugala, PATH's Chief of Africa Region. The introduction of MenFive in Nigeria heralds a transformative era in the fight against meningococcal meningitis in Africa. Building on the legacy of previous vaccination efforts, this milestone reflects over a decade of unwavering, innovative partnerships. The promise of MenFive lies not just in its immediate impact but in the countless lives it stands to protect in the years to come, moving us closer to a future free from the threat of this disease.

In 2019, WHO and partners launched the global roadmap to defeating meningitis by 2030. The roadmap sets a comprehensive vision towards a world free of meningitis, and has three goals:

With outbreaks of infectious diseases on the rise worldwide, new innovations such as MenFiveare critical in helping us fight back," saidAurlia Nguyen, Chief Programme Officer atGavi, the Vaccine Alliance, which funds the global stockpile as well as vaccine rollout in lower-income countries. "This first shipment signals the start ofGavisupport for a multivalent meningococcal conjugate vaccine (MMCV) program, which, with the required donor funding for our next five years of work, will see pentavalent meningococcal conjugate vaccinesrolled out in high-risk countries. Thanks to vaccines, we have eliminated large and disruptive outbreaks of meningitis A in Africa: now we have a tool to respond to other serogroups that still cause large outbreaks resulting in long-term disability and deaths."

Following Nigerias meningitis vaccine campaign, a major milestone on the road to defeat meningitis is the international summit on meningitis taking place in Paris in April 2024 where leaders will come together to celebrate progress, identify challenges and assess next steps. It is also an opportunity for country leaders and key partners to commit politically and financially to accelerate progress towards eliminating meningitis as a public health problem by 2030.

Link:

In world first, Nigeria introduces new 5-in-1 vaccine against meningitis - World Health Organization (WHO)

Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert

Bill Gates warned about the risk of pandemics well before COVID-19.

In 2018, he predicted that "there is a significant probability of a large and lethal, modern-day pandemic occurring in our lifetimes" because of "the continual emergence of new pathogens, the increasing risk of a bioterror attack and how connected our world is through air travel."

The same year, Gates announced a $12 million initiative to "accelerate the development of a universal flu vaccine."

Don't Miss:

Now, after a Texas man recently became infected with bird flu after close contact with an infected cow, scientists are concerned about the potential of a pandemic worse than COVID.

John Fulton, founder of Canadian pharmaceutical company BioNiagara, warns that this strand of bird flu "appears to be 100 times worse than COVID, or it could be if it mutates and maintains its high case fatality rate."

For now, the Centers for Disease Control and Prevention (CDC) is telling the public to remain calm, with its Principal Deputy Director Dr. Nirav D. Shah saying, "The risk overall for the general public remains low."

Trending: This Future of Gaming startup disrupting a $272 billion industry is now letting anyone invest for a limited time.

However, in light of the increasing number of cattle herds in America contracting the bird flu virus, Shah stresses the CDC is prepared for what may be ahead, saying, "Make no mistake, the CDC is activated as a result of these findings."

If a pandemic breaks out, investors won't have to reach too deep into history for ideas on how markets will react, given the 2020 COVID pandemic that rocked financial markets and the broader economy.

Pandemic darling mRNA vaccine-makers such as BioNTech SE (NASDAQ:BNTX) and Moderna Inc. (NASDAQ:MRNA) have seen their stocks fall 76% and 77% from their respective peaks but could be poised to bounce back if fears around the bird flu virus continue to escalate.

Story continues

Gates-backed German mRNA company CureVac (NASDAQ:CVAC) has climbed even further to reach its past all-time high, with its stock down over 97% since then.

Humanity can only hope bird flu doesn't begin to spread easily via person-to-person transmission.

From 2003 to 2016, the virus has killed over 50% of people infected, while the current bird flu outbreak has already hit at least 82 million birds across 48 states.

Read About Startup Investing:

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert originally appeared on Benzinga.com

2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Visit link:

Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After ... - Yahoo Finance

(Precision Vaccinations News)

It has become clear that Brazil is currently facing its largest dengue fever outbreak. While two dengue vaccines have been approved for use in the country, each one has its own set of issues.

As of April 12, 2024, vaccine producers are focused on protecting more Brazilians against the virus over the next year.

Sanofi Pasteur's Dengvaxia vaccine is meant for individuals aged 9-45 who already have dengue. It requires three doses and pre-administration testing.

On the other hand, Takeda's second-generationQDENGA (TAK-003)two-dose vaccine is also approved for use, but it has already sold out its production for 2024.

As of January2024, the Ministry of Healthforecastedthat 5.2 million doses will be delivered in 2024. Unfortunately, that amount will leave millions of people unprotected this year.

Furthermore, an article published by The New England Journal of Medicine in January 2024 stated that the Butantan-DVsingle-dose vaccine candidateoffers protection against all four dengue virus serotypes without regard to dengue baseline serostatus and across a wide age range.

In addition to the logistical and economic benefits, Butantan-DV rapid protection may be necessary if Brazil's dengueoutbreak accelerates.

The development of this noveltetravalent dengue vaccine began at Butantan Institute in 2010, using a formulation created by researchers affiliated with the U.S. NIH.

Based on recent phase 3 clinical trial results, Butantan Instituteplansto submit a report to ANVISAin 2024,applyingfor the vaccine's registration.

"The cost of dengue in Brazil is absurd," virologistMaurcio Lacerda Nogueira said in a press release in February 2024.

"The (Butantan-DV) vaccine is expected to reduce mortality and hospitalizations due to the disease, so the Brazilian government's investment of several hundred million reais in developing an indigenous vaccine will have a huge impact on public health."

Go here to see the original:

Brazil Produced Dengue Vaccine May Arrive in 2024 Precision Vaccinations News - Precision Vaccinations